AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
X4 Pharmaceuticals Plunges 13.99% on Price Target Cut
Generated by AI AgentAinvest Pre-Market Radar
Thursday, Aug 14, 2025 7:17 am ET1min read
Aime SummaryOn August 14, 2025,
experienced a significant drop of 13.99% in pre-market trading, reflecting a notable shift in investor sentiment towards the company.H.C. Wainwright has revised its price target for X4 Pharmaceuticals (NASDAQ:XFOR) to $3.50 from $7.00, while maintaining a Buy rating on the stock. This adjustment comes as the firm continues to monitor the company's performance and market conditions.
Despite the lowered price target, H.C. Wainwright has maintained its "Buy" rating, indicating that the firm still sees potential in the company's long-term prospects. This decision suggests that while there may be short-term challenges, the firm believes in the company's ability to overcome them and deliver value to investors.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Society Pass surges 16.92% following $3 million stock offering priced at $2.00 per share
Jan.02 2026
Vanda Pharmaceuticals shares surged 25.46% on partnership expansion with European biotech entity.
Jan.02 2026
Olaplex plunges 7.59% as broader market pressures drive investor sentiment reversal
Jan.02 2026
Real Brokerage Inc. (REAX) Surges 7.04% on Renewed Investor Confidence in Long-Term Strategic Positioning
Jan.02 2026
Vanda Pharmaceuticals shares surged 25.46% on partnership expansion and FDA Breakthrough Therapy Designation.
Jan.02 2026
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments

No comments yet